Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr.FinanceWAR:DRF +10.38%43 EV-to-EBIT is -38.09 as of Aug. 08, 2026. GuruFocus rates WAR:DRF with a GF Score™ of 43/100 and a GF Value™ of zł0.62 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 314 Credit Services companies, Dr.Finance ranks worse than 318471.02% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dr.Finance's Enterprise Value for the quarter that ended in Mar. 2026 was zł4.19 Mil.
Dr.Finance's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr.Finance EV-to-EBIT Related Terms
Dr.Finance EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Dr.Finance's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Credit Services subindustry, Dr.Finance's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr.Finance EV-to-EBIT vs Credit Services Industry
For the Credit Services industry and Financial Services sector, Dr.Finance's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dr.Finance's EV-to-EBIT falls into.
Dr.Finance's current Enterprise Value is zł4.00 Mil.
Dr.Finance's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr.Finance (WAR:DRF) has a EV-to-EBIT of -38.09 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dr.Finance and its competitors. According to the industry distribution chart, Dr.Finance ranks #999999 out of 314 companies in the Credit Services industry.
Is Dr.Finance's EV-to-EBIT too high?
Dr.Finance's current EV-to-EBIT is -38.09. Based on the distribution chart, Dr.Finance ranks #999999 out of 314 companies in the Credit Services industry, which is in the bottom quartile relative to peers. Overall, Dr.Finance has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr.Finance's EV-to-EBIT compare to V and MA?
According to the Credit Services industry distribution chart, Dr.Finance ranks #999999 out of 314 companies for EV-to-EBIT. This places Dr.Finance in the lower half of its industry. The industry median EV-to-EBIT is 22.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Credit Services company?
The median EV-to-EBIT among Credit Services companies is 22.61, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dr.Finance and its competitors. For the Credit Services industry, the median EV-to-EBIT is 22.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr.Finance's current EV-to-EBIT is -38.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr.Finance stock overvalued right now?
Based on GuruFocus' analysis, Dr.Finance (WAR:DRF) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.62, compared to a current price of zł1.10 — trading 76.6% above its estimated fair value. The current EV-to-EBIT is -38.09. Dr.Finance's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dr.Finance (WAR:DRF), the current EV-to-EBIT is -38.09 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr.Finance (WAR:DRF) Overvalued in 2026?
Based on GuruFocus' analysis, Dr.Finance stock appears to be overvalued.
The current stock price of zł1.10 is trading 76.6% above its estimated GF Value™ of zł0.62.
GuruFocus considers Dr.Finance to be Significantly Overvalued.
Key valuation signals for WAR:DRF:
EV-to-EBIT: -38.09
GF Value™: zł0.62 vs. price of zł1.10 (76.6% above fair value)
No single metric tells the full story. See the WAR:DRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr.Finance SA is a financial intermediary in the sale of loans and other financial products. It operates in the business of Working capital loans, Investment loans, Leasing, and Factoring.
43GF Score
Get the complete analysis for WAR:DRF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:DRF has been successfully added to your 
